Compare Gilead Sciences, Inc. (GILD) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Under Armour Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Under Armour Inc Class A trades at $4.88 (market cap $2.07B). The key difference: Gilead Sciences, Inc. is far larger — about 88.1× Under Armour Inc Class A's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Under Armour Inc Class A for 99 Days on average.
| GILD | UAA | |
|---|---|---|
Market Cap | $182.40B | $2.07B |
Volume | 4,469,821 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $8.14 |
52-Week Low | $116.74 | $4.17 |
Typical Hold Time | 111 Days | 99 Days |
Enterprise Value | $205.46B | $3.05B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Under Armour (UAA) trades at $4.82, down 1.23% on the day, with a mixed technical picture showing a bullish overall signal but a neutral RSI. The company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. Analyst consensus is a $5.79 price target, but the stock faces headwinds from weak consumer demand and negative cash flow trends.
The outlook is cautious; while cost discipline supports margins, persistent revenue weakness and negative profitability pose significant risks. The stock's low P/S ratio of 0.42 may attract value investors, but sustained operational improvements are needed for a durable recovery amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
